VARUBI IV is the first NK-1 RA in a ready-to-use vial1-3
- Injectable emulsion does not require reconstitution
- Single-dose vial
- Free of polysorbate 80
Please see complete dosing and administration information in the Prescribing Information.
IV, intravenous; NK-1, neurokinin 1; RA, receptor antagonist.
- VARUBI, in combination with other antiemetic agents, is indicated in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
- VARUBI is contraindicated in patients taking CYP2D6 substrates with a narrow therapeutic index, such as thioridazine and pimozide. VARUBI can significantly increase the plasma concentrations of thioridazine and pimozide, which may result in QT prolongation and Torsades de Pointes.
Get support from a unique new service to integrate VARUBI IV into your practice
Because delayed CINV shouldn't define her.
Indication: VARUBI® (rolapitant), in combination with other antiemetic agents, is indicated in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Contraindication: VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. A significant increase in plasma concentrations of thioridazine may result in QT prolongation and Torsades de Pointes.
CINV, chemotherapy-induced nausea and vomiting.
Despite antiemetic treatment,More than half are still suffering4
The majority of patients undergoing highly or moderately emetogenic chemotherapy (HEC or MEC) experience delayed chemotherapy-induced nausea and vomiting (CINV)—even when prescribed a 5-hydroxytryptamine-3 (serotonin) receptor antagonist (5-HT3 RA) and a corticosteroid.4
VARUBI® (rolapitant) as part of an antiemetic regimen:Proven protection with one dose1
Warnings and Precautions
Interaction with CYP2D6 substrates
- VARUBI is a moderate inhibitor of CYP2D6 and significantly increases the plasma concentrations of CYP2D6 substrates for at least 28 days, with inhibitory effects expected to persist for an unknown duration.
- Monitor for adverse reactions when VARUBI is coadministered with CYP2D6 substrates without a narrow therapeutic index (avoid coadministration with CYP2D6 substrates with a narrow therapeutic index, thioridazine and pimozide; see Contraindication). Consider interactions with CYP2D6 substrates before starting treatment with VARUBI.